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Background: Gene expression analysis is powerful for investigating the underlying mechanisms of Duchenne
muscular dystrophy (DMD). Previous studies mainly neglected co-expression or transcription factor (TF) information.
Here we integrated TF information into differential co-expression analysis (DCEA) to explore new understandings of
DMD pathogenesis.
Methods: Using two microarray datasets from Gene Expression Omnibus (GEO) database, we firstly detected
differentially expressed genes (DEGs) and pathways enriched with DEGs. Secondly, we constructed differentially
regulated networks to integrate the TF-to-target information and the differential co-expression genes.
Results: A total of 454 DEGs were detected and both KEGG pathway and ingenuity pathway analysis revealed that
pathways enriched with aberrantly regulated genes are mostly involved in the immune response processes. DCEA
results generated 610 pairs of DEGs regulated by at least one common TF, including 78 pairs of co-expressed DEGs.
A network was constructed to illustrate their relationships and a subnetwork for DMD related molecules was constructed
to show genes and TFs that may play important roles in the secondary changes of DMD. Among the DEGs which shared
TFs with DMD, six genes were co-expressed with DMD, including ATP1A2, C1QB, MYOF, SAT1, TRIP10, and IFI6.
Conclusion: Our results may provide a new understanding of DMD and contribute potential targets for future
therapeutic tests.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_210
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Duchenne muscular dystrophy (DMD) is a severe and
progressive inherited neuromuscular disease character-
ized by muscle fiber degeneration and central nervous
system disorders that affects 1 in 3600–6000 live male
births [1]. This disease is caused by mutations or dysreg-
ulation of the X-linked dystrophin gene. Absence of or
defects of dystrophin protein result in disruption of the
dystrophin-associated protein complex (DAPC), result-
ing in chronic inflammation and progressive muscle
degeneration [2].* Correspondence: tlj1168@163.com
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identified to be primarily responsible for the pathology,
comprehensive understanding of the downstream mecha-
nisms due to dystrophin absence is still lacking. Secondary
changes in DMD involve calcium homeostasis [3], nitric
oxide synthase [4], inflammation [5] and mast cell
degranulation [6], suggesting that the pathological
process of DMD is highly complicated. Gene expression
profile analysis is a powerful strategy to investigate the
pathophysiological mechanisms of DMD. Several gene
expression profiling studies [7-11] have been performed
earlier, providing insights into the pathology of DMD.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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changes of individual genes, without considering the
differences in gene interconnections. Since the majority
of proteins function with other proteins, differential
co-expression analysis (DCEA) would provide a better
understanding of the mechanism underlying DMD pro-
gression. The rationale of DCEA is that changes in gene
co-expression patterns between two disease statuses (case
and control) provide hints regarding the disrupted regula-
tory relationships in patients. Therefore, integrate the
information of Transcription factors (TFs) into DCEA may
detect the regulatory causes of observed co-expression
changes since TFs can regulate gene expression through
binding the cis-elements in the target genes’ promoter
regions. TFs are reported to be important in both normal
and disease states [12]. Investigation of TF activities in
mdx mice has proposed several TFs involved in DMD
pathogenesis [13]. Thus, integrative analysis of TFs and
target differential co-expression genes may provide better
understanding on molecular mechanism of the secondary
changes of DMD.
In this study, using microarray gene expression data
collected from the Gene Expression Omnibus (GEO)
database, we carried out an integrative bioinformatics
analysis. Firstly, differentially expressed genes (DEGs)
were detected and pathways enriched with DEGs were
acquired. Secondly, differentially regulated link networks
were constructed to integrate the TF-to-target informa-
tion and the differential co-expression genes. Our results
may provide new understanding of DMD and new
targets for future therapeutic tests.
Methods
Microarray data
We used two datasets (GSE6011 and GSE3307) from the
GEO (http://www.ncbi.nlm.nih.gov/geo/) database. For
further combined analysis, we only selected samples gen-
erated with the platform GPL96: [HG-U133A] Affymetrix
Human Genome U133A Array.Table 1 KEGG pathways enriched with differentially expresse
ID Pathway description
hsa05322 Systemic lupus erythematosus
hsa05416 Viral myocarditis
hsa04514 Cell adhesion molecules (CAMs)
hsa05310 Asthma
hsa04510 Focal adhesion
hsa05130 Pathogenic Escherichia coli infection
hsa04672 Intestinal immune network for IgA production
hsa05330 Allograft rejection
hsa04612 Antigen processing and presentation
hsa05332 Graft-versus-host diseaseDetection of differentially expressed genes (DEGs)
Raw data including simple omnibus format in text (SOFT)
family files and CEL files of all samples were downloaded.
The CEL files contained the expression information for
each probe. Robust Multiarray Analysis (RMA) [14] was
used for raw intensity values normalization: firstly, back-
ground noise and processing artifacts were neutralized by
model-based background correction; secondly, expression
values were set to a common scale by quantile norma-
lization; thirdly, expression value of each probe was gener-
ated by an iterative median polishing procedure. The
resulting log2-transformed RMA expression value was
then used for detecting DEGs. Statistical t test was used to
identify DEGs and the Benjamini and Hochberg procedure
[15] were carried out to correct the multiple testing prob-
lems. The threshold of significant DEGs was set as P <0.01.
Up- or down-regulation of the DEGs were determined
according to the fold-change. All of the above procedures
were performed using the R software (v3.0.3) with BioCon-
ductor and limma packages (3.12.1) and libraries [16].
Functional analysis
Differentially expressed probes were annotated based on
the SOFT files. All genes were then mapped to the
Kyoto En-cyclopedia of Genes and Genomes (KEGG)
pathways (http://www.genome.jp/kegg/) database. The
hyper geometric distribution test was used to identify
pathways significantly enriched with DEGs. In addition to
KEGG pathway analysis, DEGs were also uploaded into
the Ingenuity Pathway Analysis (IPA) software (Ingenuity®
Systems, http://www.ingenuity.com) and was associated
with the canonical pathways, molecular and cellular
functions, diseases and disorders in the Ingenuity
Knowledge Base. Fisher’s exact test was implemented to
assess the significance of the associations between
DEGs and canonical pathways, functions, or diseases.
For canonical pathways, a ratio was also computed
between the number of DEGs and the total number of












Figure 1 Ingenuity pathway analysis: the most significant canonical pathways in which differently expressed genes (DEGs) were enriched.
Table 2 Ingenuity pathway analysis: diseases and
functions related to differentially expressed genes
Name P-value # Molecules
Diseases and Disorders
Neurological disease 3.98E-15–1.20E-02 133
Skeletal and muscular disorders 2.66E-13–1.07E-02 118
Cardiovascular disease 5.89E-13–9.41E-03 75
Cancer 9.06E-11–1.14E-02 293
Psychological disorders 3.24E-10–1.13E-02 92
Molecular and Cellular functions
Cellular growth and proliferation 1.38E-14–1.12E-02 136
Cell death and survival 1.24E-13–1.20E-02 128
Cellular development 8.68E-08–1.12E-02 106
Cellular movement 1.15E-07–1.20E-02 70
Cellular assembly and organization 6.30E-06–9.41E-03 73
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The DEGs were subjected to DCEA and TF-to-target
analysis using the DCGL package (v2.0) [17] in the R
software. Human TF-to-target library was incorporated
into the package to identify differentially regulated genes
and links. A total of 215 human TFs and 16,863 targets
were included in the package. Differentially co-expressed
genes (DCGs) were firstly identified and a network was
constructed with DCGs and their shared TFs. Since dys-
regulation of DMD gene is the primary cause of the
disease, we also constructed a subnetwork surrounding
the predefined gene DMD.
Results
With the two downloaded datasets (GSE6011 and
GSE3307), expression profile of 27 DMD patients (22 from
GSE6011 and 5 from GSE3307) and 14 healthy controls
were included in this study. Dystrophin protein was absent
in all patients [9,10]. A total of 454 genes were detected to
be DEGs, including 284 up regulated genes and 170 down
regulated ones. KEGG pathway analysis revealed that
aberrantly regulated genes were enriched in 10 pathways
(Table 1). Most of these pathways (7/10) are involved in theinflammatory/immune response process, such as the im-
mune system, immune disease and infectious disease. In
addition, a DMD related pathway, the viral myocarditis
pathway, was included. The other two pathways are Cell
adhesion molecules (CAMs) and Focal adhesion.
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DEGs were enriched for epithelial adherens junction
signaling, calcium signaling, nNOS signaling in skeletal
muscle cells and some additional pathways (Figure 1).
Consistent with the KEGG pathway analysis, aberrantly
regulated genes were enriched in immune system path-
ways, such as calcium-induced T lymphocyte apoptosis,
iCOS-iCOSL signaling in T helper cells, complement
system, and antigen presentation pathway (Figure 1).
Diseases and Disorders analysis (Table 2) revealed thatFigure 2 Transcription factor (TF) regulation network for the 78 pairs
differential co-expression genes; DCL: links between DCGs.“Neurological Disease” (P = 3.98E-15–1.20E-02) was the
top disease affected by these DEGs followed by “Skeletal
and Muscular Disorders” (P = 2.66E-13–1.07E-02). “Cellular
Growth and Proliferation” (P = 1.38E-14–1.12E-02) was the
top biological function mediated by these DEGs (Table 2).
DCEA results generated 610 pairs of DEGs regulated
by at least one common TF. Among these pairs, 78 pairs
DEGs were identified as differentially co-expressed. The
expression values of a total of 25 pairs of DEGs were
positively correlated with each other. A network wasof co-expressed differently expressed genes (DEGs). DCG:
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differentially co-expressed genes and their regulatory
TFs (Figure 2). Considering the primary causative effect
of the aberrant expression of DMD, we construct a
subnetwork with DMD and its differentially co-expressed
genes (Figure 3) to illustrate genes and TFs that may play
important roles in the secondary changes of DMD
patients. As shown in Figure 3, among the DEGs which
shared TFs with DMD, six genes were co-expressed
with DMD, including ATP1A2, C1QB, MYOF, SAT1,
TRIP10, and IFI6.Figure 3 A subnetwork out of Figure 2 surrounding the predefined g
genes; DCL: links between DCGs.Discussion
The pathophysiology of DMD is highly complex, involving
the dysregulation of many downstream cascades. Gene
expression profiling is powerful for investigating the
secondary changes of DMD patients. However, previous
studies mainly focused on individual gene expression
changes, without considering the gene co-expression
pattern or the TF information. In this study, with com-
bined two DMD microarray datasets, we implemented
DCEA and constructed a TF regulated network with the
hope to provide new understanding of the pathogenesis.ene DMD. TF: Transcription factor; DCG: differential co-expression
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lysis of the DEGs revealed that pathways enriched with
aberrantly regulated genes are mostly involved in the
immune response processes. This may be due to the
infiltration of immune cells into the muscles and the ele-
vated levels of various inflammatory cytokines [18-20]. In
addition, the calcium signaling and nNOS signaling in
skeletal muscle cells pathway were found to be enriched
with deregulated genes, which is consistent with previous
findings [3,4].
DCEA results generated 610 pairs of DEGs regulated
by at least one common TF, including 78 pairs of
co-expressed DEGs. As shown in Figure 2, many TFs are
involved in the regulation of these DEGs. Since DMD is
the causative gene, a subnetwork was constructed to
illustrate important genes and TFs that may play import-
ant roles in the secondary changes of DMD patients
(Figure 3). Among the DEGs which shared TFs with
DMD, six genes were co-expressed with DMD, including
ATP1A2, C1QB, MYOF, SAT1, TRIP10, and IFI6. Among
them, ATP1A2, MYOF, and SAT1 have previously been
reported to be involved in muscular dystrophy [21-23].
The relationship between the three left genes and DMD
is still known. However, it is worth further investigation.
Take IFI6 for example, this gene was highly expressed
in muscle and bone and it is reported to inhibit cyto-
chrome c release from mitochondria by regulating the
Ca2+ channel which consequently attenuate apoptosis
[24]. Alterations in intracellular Ca2+ homeostasis are
involved in the alteration of apoptosis since a sustained
increase in cytosolic Ca2+concentration accompanies
with apoptosis in cells [25]. Previous study [26] have
demonstrated the high influx of extracellular calcium
through a dystrophin-deficient membrane, which may
lead to subsequent muscle necrosis or apoptosis along
with the inflammation response. Whether this gene
contributes to the pathogenesis through its regulation of
the Ca2+ channel needs further investigation. Among the
TFs detected in the array, several TFs of DMD are
dysregulated, including GATA2 and STAT5B. Further
studies are needed to investigate their involvement in
the disease and the mechanisms of other unmeasured
TFs (Figure 3).
The ultimate cure for DMD will lie in the stable intro-
duction of a functional dystrophin gene into the muscles
of DMD patients, however, when gene therapy or trans-
plantation of stem cells/ muscle precursor cells will be
clinically available is unpredictable. In the interim, redu-
cing secondary features of the pathologic progression of
dystrophin deficiency could improve the quality and
length of life for DMD patients. Dysregulation of the genes
which were co-expressed with DMD may be caused by
the malfunction of DMD. Therapeutic strategies aimed to
compensate for the dysregulation of these genes may helpto reduce the secondary features of DMD. Therefore,
genes co-expressed with DMD we identified here may be
considered as therapeutic targets in further investigations
to treat the secondary effects. In addition, TFs that regu-
lated these genes and DMD may also serve as potential
therapeutic markers in future studies.
Conclusions
In summary, with combined microarray data from the
GEO database, we conducted DECA and acquire the TF
information of co-expressed DEGs to capture pathogenic
characteristics of DMD. Our results may provide a new
understanding of DMD and further contribute potential
targets for future therapeutic tests.
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